News

Ignyta had previously disclosed it was in discussions with Lilly regarding the optimal path forward for taladegib in the context of its pipeline priorities, which are focused substantially

PureTech Health will develop these new product candidates in an operating subsidiary, resTORbio, with an initial focus on diseases related to immunosenescence, an age-related decline in immune function.

The trial results could not show the topical stearoyl Co-A desaturase-1, or SCD1 inhibitor, XEN801 producing any statistically considerable difference in the primary endpoint of the percent change

Pemphigus vulgaris is a severe life-threatening condition, which can be recognized by progressive painful blistering of the skin and mucous membranes. Rituxan is a type of antibody therapy,

Amgevita is authorized for the treatment of certain inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis (AS); severe axial spondyloarthritis without radiographic

Acquisition consideration consisted of a $6 million upfront payment, of which $3 million is in cash and the remainder in BioLineRx shares.  Additional future payments may be made

Bavencio, which is developed for intravenous use, has been approved to treat adults and pediatric patients aged 12 years and older with mMCC. Bavencio is a human programmed

The patent case against Biogen for Tecfidera was filed last year by Coalition for Affordable Drugs led by hedge fund manager Kyle Bass. Following the patent board’s ruling,

Akashi plans to initiate a new study, HALO-DMD-04. “We are pleased to learn that the FDA is allowing Akashi to resume the clinical development of HT-100,” said Pat